ABBV vs GOOGL: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Alphabet Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Alphabet Inc. · Communication Services
$317.41
-4.5% upside to fair value
Grade D
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
GOOGL |
| Current Price |
$208.05 |
$317.41 |
| Fair Value Estimate |
$217.50 |
$303.05 |
| Upside to Fair Value |
+4.5%
|
-4.5%
|
| Market Cap |
$367.9B |
$3,839.7B |
| Forward P/E |
14.9x
|
29.0x
|
| EV / EBITDA |
16.7x
|
21.5x
|
| Price / Sales |
6.1x
|
9.5x
|
| Price / FCF |
20.9x
|
52.4x
|
| Revenue Growth YoY |
+8.6%
|
+11.3%
|
| Gross Margin |
83.7%
|
59.7%
|
| Operating Margin |
34.7%
|
32.0%
|
| Return on Equity |
-129.24%
|
35.0%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
1.91%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Alphabet Inc. operates as a global leader in internet content and information services, primarily through its dominant search engine, advertising platforms, and cloud computing services. The company benefits from durable competitive moats including browser and mobile OS dominance, strong brand recognition, and advanced AI infrastructure investments. Despite strong revenue growth of 11.3% year-ove…
Accumulation Zones
| Metric |
ABBV |
GOOGL |
| Zone Low |
$163.13 |
$227.29 |
| Zone High |
$184.88 |
$257.59 |
| In Buy Zone? |
No
|
No
|